What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.
What Verrica Pharmaceuticals’ VP-315 data may reveal about the future of skin cancer immunotherapy
Read how Verrica Pharmaceuticals’ VP-315 data could reshape skin cancer immunotherapy and what clinicians and investors should watch next.